MicroRNA-206: a Promising Theranostic Marker

Abstract

MicroRNAs (miRs) are small non-coding RNAs that negatively regulate gene expression by binding to the 3` untranslated regions (3`UTR) of their target mRNAs. MiRs were shown to play pivotal roles in tissue development and function and are also involved in the pathogenesis of various diseases including cancer.

MicroRNA-206, which belongs to the group of so-called “myomiRs”, is one of the most studied miRs thus far. In addition to being involved in skeletal muscle development and pathology, it has also been established that it is involved in the pathogenesis of numerous diseases including heart failure, chronic obstructive pulmonary disease, Alzheimer's disease and various types of cancers.

The aim of this review is to provide a complex overview of microRNA-206, including regulating its expression, a brief description of its known functions in skeletal muscle and a complex overview of its roles in the biology and pathology of other tissues, emphasizing its significant diagnostic and therapeutic potential.

1. Introduction

MicroRNAs (miRNAs) are small non-coding RNAs, first discovered in the C. elegans nematode worm in 1993 ¹. According to the latest release of miRBase ² 20 years later, there are now over 30,000 known mature miRNA sequences described in 206 species.

MiRNA Biogenesis (Figure 1) consists of several consecutive steps with the first one being transcribing the miRNA from its corresponding gene using RNA-polymerase II/III into the molecule called primary miRNA (pri-miR). In the nucleus, pri-miR is cleaved with Drosha/DGCR8 complex to form a precursor miRNA (pre-miR) that is transported from the nucleus with exportin‑5 protein. In the cytoplasm, nuclease Dicer cleaves pre-miR, which leads to the generation of miRNA-miRNA* duplex. MiRNA* is usually degraded even though some miRNA* has been observed to function in a similar way to to miRNAs, i.e. they create a complex with Argonaut (Ago) proteins called (mi)RNA-induced silencing complex (RISC or miRISC). The miRNAs in this complex function as negative regulators of gene expression: they bind to the 3´-untranslated regions (3´-UTR) of their target mRNAs (in accordance with base complementarity) and this then leads either to target mRNA degradation or to translational inhibition ³. One miRNA usually has more than one target mRNA and one mRNA is usually targeted by more than one miRNA ⁴, which leads to the formation of a huge regulatory network which plays a pivotal role in numerous processes such as embryonic development, normal tissue functions and the pathogenesis of various diseases.

Figure 1.

MicroRNA biogenesis pathway. MicroRNAs are transcribed from corresponding genes with RNA-polymerase II/III; the primary transcript is called primary-miRNA (pri-miR). Already in the nucleus, microprocessing complex Drosha/DGCR8 cleaves pri-miR to precursor miR (pre-miR) that is transported from the nucleus with Exportin 5. In the cytoplasm, the Dicer claves pre-miR: the passenger strand (miR*) is consecutively degraded and the mature strand (miR) is incorporated into the RNA-induced silencing complex (RISC). Within the RISC, base pairing between miR and target mRNA 3´untranslated region (3´UTR) occurs leading to target mRNA degradation or translational inhibition.

This review focuses on microRNA-206 (miR-206), a vertebrate specific miRNA, which is referred to as a skeletal muscle specific myomiR ⁵. This miRNA shares the same seed sequence and at least some targets with miR-1 ², which also belongs to the myomiR family along with miR-133a, miR-133b, miR-208a, miR-208b and miR-499 (6, Figure 2); however miR-1 is expressed in both skeletal and cardiac muscles ⁷. MiR-206 is being intensively studied in various contexts: skeletal muscle development ^{8, 9}, function and pathology ^{5, 9}, heart failure ¹⁰, various types of cancers ^11-13 and other diseases ^14-16. The aim of this review is to introduce miR-206, provide a short description of its relevance in skeletal muscle biology as well as offering a more detailed description of this miRNA's role in other conditions while placing special emphasis on its theranostic potential.

Figure 2.

MyomiR family. The figure depicts the structure of a pre-miR-206 stem loop with the mature sequence indicated in a rectangle. Under the structure, there are sequences of all miRNAs from the human myomiR family with their seed sequences underlined. Next to the sequences, the miRNAs' tissue specificity is visualized.

2. Regulation of microRNA-206 expression

The gene for human miR-206 (hsa-miR-206) is localized on chromosome 6 in a bicistronic cluster together with the gene for miR-133b ². The expression of these microRNAs can be regulated on different levels including chromatin remodeling, transcriptional and posttranscriptional regulation and is also under endocrinological and environmental control.

The chromatin remodeling enzyme, high mobility group box 1 protein (HMGB1), has previously been shown to increase miR-206 levels when injected into the chronically failing hearts of experimental animals ¹⁰. In another cell type, the Th17-lymphocyte, it was reported that miR-206 and miR-133b are co-transcribed together with interleukin (IL)-17 when IL-23 is used ¹⁷. This co-transcription is specific for T-lymphocytes (IL-17 is not detectable in skeletal muscle even after IL-23 stimulation) and may be affected both by chromatin remodeling, since the IL-17 gene is located near the genes for miR-206/133b, and transcription factors (TFs) specific for IL-17, e.g. STAT3 ¹⁷.

Various TFs important for skeletal muscle development have been shown to regulate miR-206 expression during skeletal muscle development; likewise, the proper spatiotemporal expression of these TFs is critical to successfully complete myogenesis ¹⁸. One of the strongest inducers of myogenesis, and therefore also of mir-206, is Myf5 ¹⁹, which acts through MyoD ^20-22 and myogenin ¹⁹ with MEF2C enhancement ²³. Negative regulation of miR-206 expression during myogenesis is carried out via myostatin, since myostatin knockout caused upregulation of all myomiRs in experimental animals ²⁴. Whether this regulation is direct or indirect still remains to be determined. The importance of proper myostatin-mediated negative myogenesis regulation was previously documented on Texel sheep where just one SNP in the 3'UTR of myostatin created a binding site for miR-1/206, resulting in these animals' muscular phenotype ²⁵. Various autoregulatory loops which add robustness to this TF network have also been described, one of them involving Notch3 protein ²³. Notch3 expression is increased by MyoD at the beginning of muscle differentiation, thus ensuring MEF2C inhibition, which is important in the final stages of myogenesis. When cells are ready to finish the differentiation process, miR-1/206 targets Notch3, thereby inhibiting its function ²³.

In addition to the above mentioned TFs, other molecules and various signal pathways have also been shown to increase or decrease miR-206 expression in various tissues (Figure 3). Song et al. ²⁶ described a “dual inhibitory mechanism”, in which small heterodimer partner (SHP), a known nuclear transcriptional co-repressor, plays a role. In this model, SHP inhibits the expression of estrogen-related receptor γ (ERRγ) which is responsible for Ying Yang 1 (YY1) TF expression. A decrease in YY1 leads to the activation of TF activator protein 1 (AP1) and to an increase in miR-206 expression ²⁶. A study by Lu et al. ²⁷ lists other significant players involved in this regulatory mechanism: NFκB, miR-29 and miR-1. NFκB stimulates and miR-1/29 inhibits YY1 signaling, thus inhibiting or activating miR-206 expression, respectively ²⁷. Other signals inhibiting miR-206 expression include e.g. Sonic Hedgehog (Shh) ²⁸, fibroblast growth factors 2 and 4 (FGF2/FGF4) ²⁹ signaling pathways and tumor growth factor β (TGFβ) ³⁰.

Figure 3.

Regulation of microRNA-206 expression. The figure summarizes how miR-206 expression may be regulated or influenced. Red (blunt) arrows indicate inhibition/downregulation and green (sharp) arrows indicate activation/upregulation. Abbreviations are explained in the text.

The participation of thyroid hormones in the miR-206 regulation was described in mouse liver and corresponding cell line models ³¹ and in human skeletal muscle in patients with hypothyroidism ³². Thyroid hormones and their substituents decrease miR-206 levels and hypothyroidism increases its expression ^{31, 32}; accordingly, miR-206 is also proposed to serve as an important mediator of thyroid hormone function since some of the miR-206 targets (e.g. Mup1 and Gpd2) were previously shown to be regulated by thyroid hormones ³¹. Additional hormones to be considered in miR-206 regulation are estrogens, as shown in human breast cancer ³³, where miR-206 further targets estrogen receptor α (ERα), i.e. one of the factors responsible for cancer cells' ER-negative phenotype and an element affecting responsiveness to hormonal therapy ³³.

Focusing on posttranscriptional regulation, bone morphogenetic protein 2 (BMP-2) was shown to inhibit pri-miR-206 to mature miR-206 processing ³⁴. BMP-2 has previously been shown to cause C2C12 myoblast cell lineage differentiation into osteoblasts when supplemented ³⁵; this was explained by its inhibition of MyoD and myogenin activity ³⁶. This study therefore further expands our understanding of the lineage switch process with BMP-2 inhibiting miR-206, myoD and myogenin activity, resulting in the inhibition of myogenic differentiation.

Last but not least, the effect of environmental factors on miR-206 expression needs to be mentioned. Essential aminoacids are known to be important for muscle growth and as such stimulate muscle protein synthesis - along with pri-miR-206 levels ³⁷. Physical exercise was repeatedly shown not to the affect the circulating miR-206 levels ^{38, 39}, which may become an advantage when monitoring the course of muscle dystrophies because circulating levels of currently used markers (e.g. creatinkinase) are affected ^{40, 41}. Endurance training did not significantly affect the levels of circulating miR-206 either; however, the basal expression of miR-206 in muscle tissue was significantly lower after 12 weeks and it returned to the pre-training values following 2 weeks of withdrawn training ⁴². Interestingly, spaceflight has been shown to decrease miR-206 levels ⁴³. These results indicate that miR-206 is probably not involved in short-term muscle adaptation to physical exercise; however, everyday muscle activity is needed for its sustained expression and this basal expression may be reduced if these stimuli are either withdrawn (spaceflight) or chronically increased (endurance training).

3. ROLES FOR MicroRNA-206 IN SKELETAL MUSCLE

3.1 Myogenesis and muscle regeneration (Figure 4)

Figure 4.

Roles of microRNA-206 in muscle development and regeneration. MiR-206 involvement in muscle development with putative targets shown above black arrows. A comprehensive explanation may be found in the text.

Myogenesis is a complex process during which muscle progenitor cells leave the somites and migrate to final body locations where they proliferate and differentiate in order to create skeletal muscle ¹⁸. MiR-206 is currently considered an important part of the myogenesis process in humans ⁴⁴, mice ⁴⁵, zebrafish ⁴⁶, pigs ^{47, 48} and even common carp ⁴⁹. It can be specifically detected in the somites, with the highest expression in mouse embryos being detected 11.5-12.5 days post conception and tending to decrease from the 3rd day after birth ⁵⁰. If miR-206 and other miRNAs levels decrease due to Dicer knockout (this knockout results in global downregulation of most miRNAs), mice die prenatally ⁵¹. If muscle-specific Dicer knockout is performed, it results in skeletal muscle hypoplasia and defective fiber morphology indicating the important role of microRNAs in muscle development ⁵².

The mouse myoblast cell line (C2C12) is the most commonly used cell line for the study of myogenesis. When C2C12 cells are cultured under high serum conditions, they remain in a proliferating state; however, if they are switched to low serum conditions, they begin to differentiate and fuse into myofibers ⁵³. The importance of miR-206 in myogenesis is highlighted by a study by Kim et al. ⁴⁵. This study indicated that even in stable serum conditions, adding miR-206 induces C2C12 cell differentiation and vice versa - if miR-206 is blocked and serum conditions are changed, no differentiation occurs ⁴⁵.

Proper miR-206 downregulation and upregulation during different stages of myogenesis is crucial since it targets key molecules like paired box 3 (Pax3) and Pax7, both of which are important TFs for muscle progenitor cell migration and proliferation, respectively ¹⁸. At the right moment, miR-206 needs to be upregulated (via the regulatory pathways described above and including Myf5, MyoD and others') in order to initiate the muscle differentiation program. Inhibiting miR-206 expression using antagomiRs results in a delayed differentiation onset and improper migration of muscle progenitors ⁵⁴. Later, during myogenesis, miR-206 targets various genes enabling early and - subsequently - terminal differentiation ⁹, e.g. DNA-polymerase α (POL α) ⁴⁵, histon deacetylase 4 (HDAC4) ³⁰, utrophin ²¹ and connexin 43 (Cx43) genes ⁵⁵. Inhibiting POLα is important to terminate the proliferation program ⁴⁵ at the beginning of differentiation, which is promoted by removing the inhibitory effects of HDAC4 on MEF2C ³⁰. The downregulation of utrophin seems to be important later in the myogenesis process ²¹ while follistatin ²¹ and Cx43 downregulation ⁵⁵ play an important role in myocyte fusion into myofibers. This process naturally involves additional miRNAs, but a detailed description is clearly outside the scope of this review.

During myogenesis, part of the myoblasts enter quiescence, locate themselves between the basal membrane and sarcolemma ⁵⁶ and remain in a self-renewing state which maintains their ability to enter the muscle differentiation program in the future if the muscle is injured ¹⁸. In this case, miR-206 levels in SCs are downregulated, thus enabling Pax7 to increase while causing SCs proliferation ⁵⁷. After a short time, miR-206 levels return to the pre-injury state and SCs differentiate to replace the damaged rhabdomyocytes. When miR-206 is artificially added to injured skeletal muscle, it promotes muscle healing as shown in rat models in a study conducted by Nakasa et al. ⁵⁸.

3.2 Innervation, reinnervation and amyotrophic lateral sclerosis (ALS)

In order to properly perform its function, skeletal muscle must be properly innervated; during innervation, skeletal muscle tissue cooperates with axons in order to create neuromuscular junctions (NMJ) (Figure 5). MiR-206 levels were found to be increased in NMJ ⁵⁹, facilitating mutual communication between muscle fibers and motoneuron axons by targeting various molecules including brain-derived neurotropic factor (BDNF) and its receptor (p75^NTR) ⁶⁰, HDAC4 ⁵⁹ and MEF2 ⁶¹.

Figure 5.

MicroRNA-206 involvement in neuromuscular junctions function. The figure depicts neuromuscular junction (NMJ) with the neural cell marked in blue and muscle cell in red. During transmission (marked as yellow thunderbolts), myoD expression is enhanced, leading to the expression of miR-206, which further affects mutual communication between muscle and neural cell and affects reinnervation after denervation.

The experiments focused on reinnervation after a sciatic nerve injury showed that miR-206 expression remained unchanged immediately after denervation; however, it increased during the reinnervation process ⁶¹. By targeting MEF2, miR-206 was proposed to affect muscle composition (fiber type) and to constitute one of the sources of the differences observed between healthy and reinnervated muscle ⁶¹. However, these results were not confirmed by a subsequent study where miR-206 levels remained unchanged both after denervation and during reinnervation; the role of other myomiRs was thus emphasized ⁶².

Reinnervation has also been intensely studied in amyotrophic lateral sclerosis (ALS) ^{59, 63}. ALS is a neurodegenerative disease which causes a loss of motoneurons, resulting in the denervation of skeletal muscle, consequent paralysis and death ^{59, 63}. MiR-206 levels were shown to be upregulated in both mice ⁵⁹ and humans ⁶³. In the mouse model, the effects of miR-206 were analyzed in detail using miR-206 knockdown animals. Although the ALS onset in these animals was the same as wild type animals, the progression of ALS was faster, resulting in a more severe phenotype, delayed reinnervation and subsequent over-innervation with motoric axons sprouting beyond the original NMJ area ⁵⁹. HDAC4, a miR-206 target was suggested to play a role in these effects and the entire signaling pathway, including miR-206/HDAC4/FGFBP1/FGF, was suggested as an explanation of these processes ⁵⁹. In human ALS samples, miR-206 was upregulated in both slow and rapid progression patients and only levels of HDAC4 served to distinguish between these groups, indicating that other signals are also necessary for the reinnervation process ⁶³.

3.3 Muscular dystrophies

Muscular dystrophies (MD) represent a group of heritable diseases whose common sign is muscle weakness, often in a progressive form ⁶⁴. The most common X-linked and autosomal dominant MDs are Duchene MD and myotonic dystrophy type 1 (MDT1) respectively ^{64, 65}. The first study to report the dysregulation of myomiRs in Duchene MD was conducted by McCarthy et al. using mdx mice ⁶⁶. The study showed that miR-206 is downregulated in the plantaris muscle, but is increased in the diaphragm, most likely due to the upregulation of MyoD and possibly due to the functional denervation of the regenerating muscle ⁶⁶. Roberts et al. further confirmed that miR-206 levels also differ between muscle groups in an experimental animal ⁶⁷. It was also shown that miR-206 increase occurs during muscle regeneration ^{68, 69} and, since the diaphragm is the most affected muscle in mdx mice ⁶⁶, high expression of miR-206 may indicate a high regenerative capacity of this muscle. Interestingly, Yuasa et al. reported that in CXMD_J dogs, which display a more severe phenotype than mdx mice, miR-206 levels are not increased, which may reflect insufficient regeneration ⁶⁸. All of the above mentioned information correlates with a subsequently reported observation, i.e. that miR-206 may be found mostly in satellite cells where it stimulates their differentiation in order to initiate muscle regeneration ⁷⁰.

In MDT1, the miR-206 dysregulation and other muscle-specific miRNAs were described several years later ^{71, 72}. Whether miR-206 levels are upregulated ⁷² or unchanged ⁷¹ still remains to be elucidated by more extensive studies; however, in MDT1 patients, miR-206 is mislocalized within the cell compared to normal muscle tissue ^{71, 72}.

The above mentioned studies clearly indicate that miR-206 is extensively involved in the pathophysiology of various muscle dystrophies. From a theranostic point of view, miR-206 levels (along with miR-1 and miR-133) were shown to be good serum biomarkers for DMD, correlating even with the severity of the disease ^{40, 67}. Since their levels are not affected by physical exercise ^38-40 they may serve as more precise and valuable biomarkers than the currently used creatinkinase. Current studies also suggest that miR-206 may be used as a therapeutic tool in muscular dystrophy thanks to its reported pro-differentiating and disease-progression slowing effect ^{67, 73} (Figure 6).

Figure 6.

Roles of microRNA-206 in muscular dystrophies. The figure represents miR-206 involvement in muscle dystrophies (MD). The upper left circle emphasizes its role in MD pathophysiology, i.e. involvement in muscle regeneration and differentiation and being differentially expressed in distinct muscle groups. The upper right circle shows its possible use as a circulating biomarker of MD and its correlation with patient prognosis. The lower circle shows the potential to use miR-206 mimics in the treatment of MD.

4. MIR-206 IN TUMOR BIOLOGY (Figure 7)

Figure 7.

MicroRNA-206 in tumors. The figure summarizes various cancer types where miR-206 levels and roles were investigated. The colors of the boxes on both sides correspond to the colors of the organs indicated in the human outline. The arrows indicate whether miR-206 levels are upregulated or downregulated.

4.1 Rhabdomyosarcoma

Rhabdomyosarcoma represents the most common soft tissue sarcoma with embryonal RMS (ERMS) being the most common type, followed by alveolar RMS (ARMS) ⁷⁴. Both of these tumors express markers specific to skeletal muscle; however, their cells are much less differentiated in comparison with muscle tissue ⁷⁵. Although the downregulation of miR-206 (and other myomiRs) has been observed repeatedly in both types, it is more prominent in ARMS, thus partially explaining its less differentiated phenotype and more aggressive clinical behavior ^76-78.

Experiments reinducing miR-206 in RMS cell lines have led to decreased cell proliferation and migration properties and increased myogenic differentiation ^{76, 77}. Expression profiling in the RD18 ERMS cell line identified more than 700 mRNA levels to be affected by miR-206 transfection ⁷⁷. Cell line experiments were further extended by injecting miR-206 directly into RMS mouse models which caused a significant decrease in tumor mass and an increase in the expression of differentiation markers implicating miR-206 as a RMS therapy ^{76, 77}.

Clinical trials focusing on the association between miR-206 and RMS have also been conducted, resulting in circulating miR-206 being identified as a potent diagnostic marker: the levels of this microRNA are muscle-specific even if this microRNA is downregulated in RMS tissue and its circulating levels are higher in RMS patients than in healthy controls ⁷⁹. MiR-206 also provides information about the prognosis of a patient: tumors expressing lower miR-206 levels are considered more aggressive with a poorer prognosis ⁸⁰.

4.2 Breast cancer

Breast cancer is the most common cancer in women ⁸¹. In most cases, ERα is present and provides an enormous theranostic potential: its presence facilitates both disease classification and the tailoring of individual therapy. MicroRNA array analysis identified microRNA deregulations in this cancer ⁸² with miR-206 being increased in ERα negative and decreased in ERα positive breast cancer ^{83, 84}. ERα was repeatedly shown to be a target for miR-206 ^{33, 83, 85, 86} and two miR-206 binding sites were found to be localized in its 3´UTR, along with binding sites for a number of additional miRNAs ³³. Moreover, miR-206 also targets steroid receptor coactivators (SRC)-1 and SRC-3 and TF GATA-3, all of which are part of estrogen-mediated signaling pathways; miR-206-mediated inhibition thus disrupts estrogen signaling on more levels than simply affecting ERα expression ⁸⁷.

MiR-206 levels and activity in breast cancer are subject to the influence of numerous factors. Estradiol activation of ERα causes miR-206 downregulation ³³; however, this regulatory circuitry may be distracted by epidermal growth factor (EGF) signaling (applying both estradiol and EGF does not decrease miR-206) partly through the EGF-receptor/MAPK pathway ⁸⁷. On the contrary, miR-206 activity may be increased when ellagic acid is used ⁸⁸ or when a single nucleotide polymorphism (rs9341070) in ERα 3´UTR is present - as it increases miR-206 binding ³³, or when Ago-2 protein levels are increased - as observed in breast cancer cells ⁸⁹. The factors contributing to increased miR-206 activity also contribute to ERα negativity ⁸⁹ and consequently to a poorer prognosis.

Thus far, applying miR-206 to breast cancer cell lines has been shown to decrease cell growth ^{83, 85} due to cell cycle arrest ^{11, 83, 86} and to decrease cell proliferation following estradiol stimulation ⁸⁶. Underlying cell growth decrease mechanisms include the cyclinD2 downregulation, an important molecule inducing cell cycle entry ¹¹ and hepatocyte growth factor receptor (MET) downregulation ⁸⁵. These results indicate miR-206's future therapeutic potential in breast cancer therapy.

MiR-206 has also been identified as a metastasis-preventing microRNA ⁹⁰ and its decreased levels have been associated with advanced clinical stages and the presence of lymph node metastasis ⁹¹. Even if its levels do not correlate with prognostic parameters, pre-miR-206 SNP (rs6920648) presence affects patient survival (HR 0.77, p = 0.02), with stronger associations being observed in Caucasians and women with ER+ tumors than in African Americans ⁹². However, how exactly this SNP affects miR-206 biogenesis still remains to be clarified.

4.3 Other cancers

As miR-206's potential roles in other cancers are currently being intensely studied, only a limited number of studies are currently available (Table 1). Some of these studies focus on the microRNA profiling of specific cancers ^93-95, others evaluate the potential link of miR-206 expression levels to the clinical outcomes of individual patients ^{96, 97} and still others evaluate the miR-206's potential use in treatment ^{12, 98}.

Table 1.

Overview of miR-206 roles in other cancers

Cancer	Significance of miR-206	Ref.
Endometrial cancer	In ERα+ endometrial endometroid carcinoma, miR-206 levels are decreased and correlate negatively with ERα levels.	101
	Introduction of miR-206 causes cell cycle arrest and affects invasiveness.
Colorectal carcinoma	Lower expression of miR-206 indicates worse prognosis.	96
	Prognostic signature of miR-206 and additional four miRs (let-7a, miR-21, miR-135a, miR-335) may be used to detect metastases.
	Downregulation of miR-206 dysregulates miR-206/KLF-4 feedback loop which is involved in cancer development.	102, 103
Gastric cancer	Low expression of miR-206 indicates presence of metastases, venous invasion and higher probability of hematogenous recurrence along with shortened overall survival.	12, 97
	MiR-206 targeting of cyclinD2 is partially responsible for decrease in cell growth and impaired colony growth of gastric cancer cell lines.	12
Lung cancer	Low expression of miR-206 was detected in samples with metastasis.	13
	Transfection of miR-206 caused decrease in cell proliferation, migration and invasion and induced apoptosis.
	Lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone increases levels of miR-206 (and miR-133b) in plasma of exposed rats.	104
Osteosarcoma	MiR-206 is one of the downregulated microRNAs in osteosarcoma.	105
Naso-pharyngeal carcinoma	MiR-206 is one of 13 identified microRNAs suggested to play important roles in nasopharyngeal carcinoma development.	106
	Levels of miR-206 increased when lymph node metastasis were present.
Laryngeal cancer	Levels of miR-206 are downregulated in laryngeal carcinoma patients.	99
	Induction of miR-206 in cancer cell lines causes decrease in viability and invasive potential and increase in apoptosis.
	Application of miR-206 into mouse model leads to significant decrease in tumor mass.
Ovarian cancer	MiR-206 is higher in CD133+ cells (ovarian cancer stem cells) compared to CD133- cells.	93
Prostate cancer	MiR-206 expression does not change during the progression of prostate cancer from intraepithelial neoplasia to metastases.	107
Renal cell carcinoma	MiR-206 is downregulated in clear cell renal cell carcinoma and inhibits cancer cell proliferation.	94, 108
Prolactinoma	Bromocriptine treatment increases levels of miR-206 in prolatinomas which may partly explain bromocriptine-induced apoptosis.	98
Vestibular schwannoma	MiR-206 is significantly downregulated in schwannoma cells.	95
Glioma and neuroblastoma	MiR-206 is downregulated in tumor cell lines and its transfection leads to apoptosis, in part by targeting Otx2.	109
Waldenström macro-globulinemia	MiR-206 levels are upregulated in Waldenström macroglubulinemia cells accounting for modulation of histon deacetylation in part by targeting HAT (Myst3) protein.	110

The studies reviewed in Table 1 clearly indicate that the downregulation of miR-206 is associated with poorer patient prognosis, most notably due to the increased metastatic potential of the listed cancers ^{13, 96, 97}. A potential explanation for this phenomenon may be found in the miR-206 targeting of VEGFA, an important angiogenesis factor, as shown in laryngeal cancer ⁹⁹ or during zebrafish development ¹⁰⁰. In the latter study, miR-1/206 knockdown zebrafish exhibited larger intersegmental vessel diameter and an increased number of endothelial cells ¹⁰⁰. While this finding needs to be further confirmed on different tumors and in larger cohorts, it may be hypothesized that miR-206 downregulation is a general sign of tumorigenicity which enables neoangiogenesis and the proliferation of tumor cells.

5. ROLES FOR MIR-206 IN OTHER TISSUES AND DISEASES

5.1 Myocardial infarction, heart failure and dilated cardiomyopathy

Various studies indicate that in spite of the muscle-specific character of miR-206, it may also play a pivotal role in the heart muscle ^{10, 111, 112} and associated conditions. The first study connecting miR-206 to the heart was conducted by Shan et al. ¹¹² and showed that in a mouse model of myocardial infarction, levels of miR-1 and miR-206 are increased in infarcted tissue ¹¹². The authors suggest that both selected miRs may be involved in apoptotic signaling via IGF-1, leading to cardiomyocyte dysfunction ¹¹². The same group also showed that myocardial injury is further promoted by miR-206 targeting heat-shock protein 60 (Hsp60) in in vitro and in vivo models of diabetes. An increase in miR-1 and miR-206 was probably induced by a MEK1/2 increase which caused a serum response factor (SRF) increase which induced the expression of the above mentioned miRNAs by binding to specific response elements (RE 2,3,4 for miR-1 and RE5 for miR-206) ¹¹¹. A miR-206 increase was also observed in a rat model of heart failure and was even more prominent in mice treated with HMGB1 ¹⁰. Administering HMGB1 improved cardiac function along with collagenolytic activity and decreased cardiac remodeling in experimental animals. These effects may be at least in part explained by an miR-206-induced decrease in tissue inhibitor of metalloproteinase 3 (TIMP-3) levels, thus enabling an increase in matrix metalloproteinase (MMP)2 and MMP9 ¹⁰.

Last but not least, miR-206 is involved in E2F6-induced dilated cardiomyopathy (DCM) ¹¹³. E2F6 represses the EF2/Rb signaling pathway; transgenic mice in which E2F6 expression was sustained until adulthood generally present with DCM leading to heart failure. E2F6 dysregulation in Tg mice was associated with ERK pathway activation leading to an increase in miR-206 levels and Cx43 downregulation leading to DCM and electrical instability ¹¹³ (Figure 8).

Figure 8.

Roles for microRNA-206 in cardiac diseases. In a healthy heart, miR-206 levels are barely detectable. In diseased conditions, its levels increase, leading to the apoptosis of the cells after myocardial infarction or in some cases, diabetic cardiomyopathy. In E2F6-induced dilated cardiomyopathy cases, increased miR-206 levels lead to electrical instability. However, heart failure cases, miR-206 overexpression seems to improve cardiac function and positively affect cardiac remodeling.

5.2 Pulmonary hypertension, COPD and infectious respiratory diseases

It has been suggested previously that the development of pulmonary artery hypertension (PAH) resembles tumor growth to a certain degree, especially due to the devastating proliferation of smooth muscle cells (SMC) ¹¹⁴. As in the case of tumors, mouse models of pulmonary hypertension have likewise shown downregulated miR-206 levels in examined tissue ^{14, 115} and upregulated in serum ¹⁴. However, other recently conducted studies present contradictory results. Jalali et al. showed that transfecting miR-206 to pulmonary artery SMCs (PASMCs) caused a decrease in proliferation and cellular migration and an increase in apoptosis, probably due to a decrease in Notch3 signaling. Notch3 is a known repressor of SMC differentiation and miR-206-mediated inhibition results in an increase of SMC differentiation markers, such as calponin and SM specific α-actin. Notch3 is also known to be involved in the pathogenesis of PAH and its inhibition by miR-206 may serve as a potential treatment for PAH in the future ¹¹⁵. Contradictory results, namely a miR-206-mediated increase in proliferation, has been observed in a study by Yue et al.; miR-206 was shown to target HIF-1a, thus affecting the HIF-1a/Fhl-1 pathway; however, miR-206 transfection paradoxically led to an increase in HIF-1a levels ¹⁴. Future studies are therefore needed to shed more light on the role of miR-206 in PAH pathogenesis.

Furthermore, it is known that PAH often develops as a result of COPD ¹¹⁶. Increased levels of miR-206 and other muscle-specific miRs were established in COPD patients sera samples; these levels negatively correlated with the function of the quadriceps muscle ¹⁶ in which miRNA expression analysis previously showed altered miRNA expression ¹¹⁷. An increase in serum levels of miR-206 is probably the result of increased muscle turnover, fiber type shift and muscle wasting in COPD patients; circulating miR levels may thus serve as biochemical markers of muscle performance ¹⁶.

MicroRNAs have also been shown to play a role in infectious respiratory diseases as they participate in agent-host interactions ¹¹⁸. Using porcine models, miRNA expression profiles were found to be changed and miR-206 levels being upregulated in both porcine reproductive and respiratory syndrome virus (PRRSV) ¹¹⁸ and influenza virus ¹¹⁹ infections. Targeting viral RNAs and mRNAs of various inflammatory molecules (determined using computational prediction) indicates potential roles for miR-206 in antiviral response ^{118, 119}.

In humans, miR-206 serum levels have been proven to be differentially expressed in pertussis patients in comparison with healthy controls ¹²⁰. Using a panel of five microRNAs (miR-202, miR-342-5p, miR-206, miR-487b, miR-576-5p), the authors were able to diagnose pertussis with a sensitivity of 97.4 % and a specificity of 94.3 % (cut off 0.707) ¹²⁰.

5.3 Central nervous system

The brain is the most complex organ in the human body. Various miRNAs were shown to be upregulated or downregulated in distinct parts of the brain, which therefore supports their possible area-specific functions: e.g., miR-206 is detected at higher levels in the cerebellum than in the amygdala, the hippocampus or substantia nigra of adult male rats ¹²¹. In a healthy brain, however, miR-206 can be detected only at very low levels, which may be important for proper neural system development: introducing miR-206 into the oligodendrocyte cell line CG-4 causes a decrease in tubulin polymerization-promoting protein (TPPP)/p25, which results in inhibiting oligodendrocyte differentiation ¹²².

An increase in miR-206 levels has been observed in various pathological conditions and has been shown to be of theranostic significance ^123-125. During ischemia/reperfusion injury of the brain ¹²³, miR-206 levels correlate with infarct size in a rat embolic stroke model, i.e. its levels increase during the first two days, followed by a continuous decrease ¹⁵. Similar correlations were observed in mRNA levels of genes controlled by miR-206 (BDNF, Notch3, Cx43 and Otx2) ¹⁵. MiR-206 levels are also upregulated in Alzheimer's disease; downregulation reached by the delivery of antagomiRs (either directly intraventricularly or indirectly intranasally) caused a prominent increase in memory function, synaptogenesis and neurogenesis in the hippocampus ¹²⁴. This may serve as a promising strategy for future Alzheimer's disease management. Last but not least, with respect to schizophrenia, miR-206 SNPs (rs17578796 and rs1700) were associated with the occurrence of this disease ¹²⁵. MiR-206 was shown to target genes previously associated with schizophrenia ^{125, 126} while also targeting the RNAs of several viruses (e.g. coxsackievirus B2, poliovirus 1) which were shown to affect neural cell function ¹²⁶.

5.4 Other roles of microRNA-206

MicroRNA-206 has already been found to be involved in posttranscriptional regulation of numerous processes throughout the body and seems to be potentially useful in clinical practice. Other organs, diseases and conditions where miR-206 was shown to play a role are summarized in Table 2 and it may be expected that more roles for miR-206 will be provided in the near future.

Table 2.

Roles of miR-206 in other diseases

Tissue	MiR-206 significance	Ref
Scleroderma	MiR-206 along with miR-21 may serve as a potential diagnostic tool for scleroderma.	127
Pain control	MiR-206 inhibits the expression of substance P from its mRNA in human mesenchymal-stem-cells-derived neuronal cells.	128
	MiR-206 levels are changed in dorsal root ganglion and spinal cord dorsal horn in CFA-induced inflammatory response or during sciatic nerve ligation.	129
Biorhythms	MiR-206 is a part of the MyoD-miR-206-CLOCK-MyoD regulatory loop and thus participates in circadian rhythms regulation.	130
Brown adipose tissue	MiR-206 expression is abundant in brown adipocytes and is missing in white adipocytes. This supports the idea that brown adipocytes and myocytes originate from a common cell lineage.	131
Liver steatosis	MiR-206 suppresses liver X receptor α (LXRα) levels, thus inhibiting lipogenesis and serving as a potential therapeutic tool for future treatment of lipogenesis-associated diseases such as liver steatosis.	132

6. Conclusions

Under physiological conditions, miR-206 may be skeletal-muscle-specific ^{5, 7}; however, under pathological conditions, its pleiotropic character is shown to be involved in the pathogenesis of various diseases, including heart failure ¹⁰, different types of tumors such as rhabdomyosarcoma ^{22, 76, 77} and breast cancer ^{11, 33, 83, 91} or neurological disorders such as Alzheimer's disease ¹²⁴. In most of the above mentioned diseases, miR-206 levels are downregulated, which leads to the recognition of this miRNA as “disease-preventing”. In muscle dystrophies, where miR-206 is upregulated, this upregulation seems to be of “self-treating” significance ^{66, 73}. Alzheimer's disease is an exception from this “disease-preventing rule”, since in this case miR-206 upregulation does more harm than good by decreasing levels of BDNF, a molecule involved in neuronal plasticity and other brain functions ¹²⁴.

MiR-206's importance is further highlighted by the many factors known to be involved in its regulation. The complex network of regulatory mechanisms results not only in miR-206's tissue-specific expression ⁷ but also in area- or locality-specific expression as shown in various types of muscle ^{66, 67} and distinct parts of the brain ¹²¹. Whether these slight differences affect the precise functions of the above mentioned tissues (e.g. by affecting fiber type or neurotransmission), must be determined by future studies.

Using many examples, miR-206 was shown to have great theranostic potential for future clinical practice, serving as a disease biomarker, a disease progression and patient prognosis marker and in some cases even serving as a treatment tool.

To diagnose a disease, more than one miRNA is generally necessary and more miRNAs create a specific pattern which facilitates the ability to distinguish different diseases. While MiR-206 is very often part of these patterns, its elevated circulating levels on their own may also be enough to identify patients with rhabdomyosarcoma ⁷⁹ or to assess the severity of muscle wasting in patients with COPD ¹⁶.

With respect to the therapeutic potential of miR-206, both currently suggested methods using miR mimics and antagomiRs may be used ¹³³. Using miR-206 mimics should lead to its level restoration in diseased tissue and the restoration of many target protein levels and thus to an improvement of the disease or its cure. This has already been suggested for rhabdomyosarcoma ^{76, 77}, muscle dystrophies ⁷³ and pulmonary hypertension ¹³⁴. AntagomiR against miR-206 may - on the other hand - offer a promising strategy to deal with Alzheimer's disease ¹²⁴.

Using miRNAs as treatment tools is currently becoming a reality since there are biotech companies focusing on the use of miRNAs in diagnostics as well as pharmaceutical companies finalizing preclinical research phases and proceeding to clinical trials. In the case of liver cancer, one of the miRNAs, miR-34a, has already entered Phase I (NCT01829971). In the case of miR-206, MiRagen therapeutics is now in the “lead optimization” phase of research for using this miRNA as treatment for neuromuscular disorders ¹³¹.

In conclusion, miRNAs, and especially miR-206, have great theranostic potential; its real significance will most likely be determined in the very near future.

Abbreviations

miRNA/miR

microRNA

mRNA

messenger RNA

DGCR8

DiGeorge syndrome critical region 8

UTR

untranslated region

Ago

Argounat

hsa

homo sapiens

HMGB1

high mobility group box 1 protein

IL

interleukin

TF

transcription factor

MyoD

myocyte differentiation

MEF2C

myocyte enhancer factor 2C

SHP

small hetodimer partner

ERRγ

estrogen-related receptor γ

YY1

Ying Yang 1

AP1

activator protein 1

NFκB

nuclear factor κ B

Shh

Sonic Hedgehog

TGFβ

tumor growth factor β

FGF2

fibroblast growth factor 2

FGF4

fibroblast growth factor 4

ERα

estrogen receptor α

BMP-2

bone morphogenetic protein 2

Pax3

paired box 3

Pax7

paired box 7

POLα

DNA-polymerase α

HDAC4

histon deacetylase 4

Cx43

connexin 43

SCs

satellite cells

NMJ

neuromuscular junction

BDNF

brain-derived neurotropic factor

ALS

amyotrophic lateral sclerosis

FGFBP1

fibroblast growth factor binding protein 1

FGF

fibroblast growth factor

MD

muscular dystrophy

mdx

muscular dystrophy

DMD

Duchene muscular dystrophy

MDT1

myotonic dystrophy type 1

CXMD_J

canine X-linked muscular dystrophy

RMS

rhabdomyosarcoma

ERMS

embryonal rhabdomyosarcoma

ARMS

alveolar rhabdomyosarcoma

SRC1

steroid receptor coactivator 1

SRC3

steroid receptor coactivator 3

EGF

epidermal growth factor

MAPK

mitogen activated protein kinase

MET

hepatocyte growth factor receptor

SNP

single nucleotide polymorphism

VEGF

vascular endothelial growth factor

KLF-4

Krüppel Like-Factor 4

CD

cluster of differentiation

Hsp

heat-shock protein

RE

response elements

TIMP-3

tissue inhibitor of metalloproteinase 3

MMP

matrix metalloproteinase

DCM

dilated cardiomyopathy

PAH

pulmonary artery hypertension

SMC

smooth muscle cells

PASMC

pulmonary artery SMC

HIF

hypoxia-inducible factor

COPD

chronic obstructive pulmonary disease

PRRSV

porcine reproductive and respiratory syndrome virus

TPPP

tubulin polymerization-promoting protein

LXRα

liver X receptor α